Cardioprotection by endogenous fibroblast growth factor 2 in cardiac ischemia-reperfusion injury in vivo

Similar documents
Fibroblast growth factor 2 is an essential cardioprotective factor in a closed-chest model of cardiac ischemiareperfusion

Genetic ablation of Acp1 (Lmptp) in mice prevents heart failure

Supplementary Figure 1. Confocal immunofluorescence showing mitochondrial translocation of Drp1. Cardiomyocytes treated with H 2 O 2 were prestained

Gender differences in the prevalence and patterns of alcohol use among 9th-12th graders in a St. Louis suburban high school

c Ischemia (30 min) Reperfusion (8 w) Supplementary Figure bp 300 bp Ischemia (30 min) Reperfusion (4 h) Dox 20 mg/kg i.p.

DECLARATION OF CONFLICT OF INTEREST

The Role of FGF Signaling in the Regulation of Adult Murine Cardiomyocyte Contractility and Pathologic Hypertrophy

Viral infections in airway remodeling

Supplementary Figure 1. Spatial distribution of LRP5 and β-catenin in intact cardiomyocytes. (a) and (b) Immunofluorescence staining of endogenous

Ischaemic Preconditioning prevents the differentiation induced by ischaemia/reperfusion injury of rat cardiac fibroblast to myofibroblast

Gene expression was analyzed by real time PCR (SYBR GREEN PCR Master. Mix, Roche Applied Science) using specific oligonucleotides.

SUPPLEMENTARY INFORMATION

Common and unique genetic contributions to conduct disorder and two stages of alcohol dependence development in women

Mesenchymal Stem Cells to Repair Vascular Damage after Chemotherapy: Past, Present and Future

Tissue repair. (3&4 of 4)

Endothelial PGC 1 - α 1 mediates vascular dysfunction in diabetes

E. Cervio, P. Danieli, C. Ciuffreda, F. Pisano, M. Roccio, M. Gnecchi. The authors have no financial disclosures to declare

Cardiovascular disease (CVD) is the primary cause of

When is strain assessment mandatory?

Repetitive myocardial ischemia promotes coronary growth in the adult mammalian heart

The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy

Do genetic influences on abuse and dependence overlap? Explorations using cannabis and alcohol diagnoses

Repetitive stimulation of autophagy-lysosome machinery by intermittent fasting preconditions the myocardium to ischemia-reperfusion injury

Race, tobacco, and alcohol in a high risk family study

Detection and Assessment of MI: Use of Imaging Methods. Robert O. Bonow, M.D.

1. Cardiomyocytes and nonmyocyte. 2. Extracellular Matrix 3. Vessels שאלה 1. Pathobiology of Heart Failure Molecular and Cellular Mechanism

Reactive oxygen species: Importance for ischemia/reperfusion (injury)

Stimulant users are sensitive to the stimulant properties of alcohol as indexed by alcohol-induced heart rate increase

Supplemental Figure I

Early cigarette use behaviors and alcohol

Uncovering the mechanisms of wound healing and fibrosis

In Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison

Fuel the Failing Heart: glucose or fatty acids? Rong Tian, MD, PhD Mitochondria and Metabolism Center University of Washington, Seattle

Cardiovascular Diseases (BMM9) and Getting to Know CNIC course Course

The association of early risky behaviors and substance dependence and depression in an ethnically diverse sample

Extracellular matrix Basic and translational science: Highlights of the congress

Myocardial Infarction

Qualitative and Quantitative Assessment of Perfusion

Heart Failure with Preserved Ejection Fraction: Mechanisms and Management

E10.5 E18.5 P2 10w 83w NF1 HF1. Sham ISO. Bmi1. H3K9me3. Lung weight (g)

Postn MCM Smad2 fl/fl Postn MCM Smad3 fl/fl Postn MCM Smad2/3 fl/fl. Postn MCM. Tgfbr1/2 fl/fl TAC

Challenging Issues in Cardiac Biomarker interpretation. F. Nikaeen. MD interventional Cardiologist

Basic Mechanisms of Remote Ischemic Conditioning

Topically Applicable Stromal Cell Growth Factors - Encapsulated Cosmeceuticals

Devices are So Old School: The New World of Myocardial Regeneration

Nature Genetics: doi: /ng Supplementary Figure 1. Parameters and consequences of mononuclear cardiomyocyte frequency.

MR Assessment of Myocardial Viability

Alterations in cardiomyocyte function during diastolic heart failure

Coronary heart disease (CHD)

I have no financial disclosures

1) Severe, crushing substernal chest pain 2) radiate to the neck, jaw, epigastrium, or left arm. 3- rapid and weak pulse 4- nausea (posterior MI).

Inflammation in heart failure: biomarker, bystander or mediator

Antifibrotic Therapy Delays Progression from Paroxysmal to Persistent Atrial Fibrillation

J Jpn Coll Angiol, 2009, 49:

Progression of atrial fibrillation: can we prevent it? Early catheter ablation will stop progression of atrial fibrillation pro

Mast Cell Tryptase Modifies The Contraction Of Human Joint Capsule Cells In Vitro

Biomarkers in cardiovascular disease. Felix J. Rogers, DO, FACOI April 29, 2018

Am J Physiol Heart Circ Physiol 304: H1382 H1396, First published March 11, 2013; doi: /ajpheart

HYPERTENSION AND HEART FAILURE

Previous MI with no intervention

Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury

DOWNLOAD PDF CARDIAC REMODELING AND CELL DEATH IN HEART FAILURE

Exercise in Adverse Cardiac Remodeling: of Mice and Men

3/27/2014. Introduction.

Remodeling the failing heart: : the biology and future treatment options

Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece

Ventricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center

Supporting Information. Calculation of the relative contributions of myocyte proliferation, stem cell. Supporting Information Fig 1 (page 9)

Pathophysiology of Coronary Microvascular Dysfunction

9/23/2017. Prof. Steven S. Saliterman. Department of Biomedical Engineering, University of Minnesota

Smoking in offspring of alcoholic twins

Fibroblast Growth Factor-2 Regulates Myocardial Infarct Repair

Structural abnormalities of the heart and vascular system in CKD & Dialysis - Thick but weak

Preserved EF with heart failure (HF pef) 50% 5 year survival. Both have type 2 diabetes Both have hypertension Both have normal ejection fractions

2228 FEBS Journal 280 (2013) ª 2013 The Authors Journal compilation ª 2013 FEBS

Qualifying Examination (Part I)

European Society of Cardiology Congress DONOR AGE NEGATIVELY INFLUENCES THE CYTOPROTECTIVE PARACRINE EFFECTS EXERTED BY HUMAN MESENCHYMAL STEM CELLS

Tissue renewal and Repair. Nisamanee Charoenchon, PhD Department of Pathobiology, Faculty of Science

Cardiac MRI: Cardiomyopathy

IRB consortia as an approach to facilitating effective and efficient reviews

Molecular Basis of Cardioprotection by Erythropoietin

Martin G. Keane, MD, FASE Temple University School of Medicine

Prolactin and its cleaved 16-kDa subform. enhance myocardial injury after ischemia/reperfusion

Atrial fibrillation and stroke. Isabelle C Van Gelder University Medical Center Groningen The Netherlands

Tcf21 MCM ; R26 mtmg Sham GFP Col 1/3 TAC 8W TAC 2W. Postn MCM ; R26 mtmg Sham GFP Col 1/3 TAC 8W TAC 2W

Nox-Dependent Mechanisms of Cardiomyocyte Dysfunction in a Model of Pressure Overload

Australian children of alcoholic female twins

The Cardiovascular System and Aging- Is it Built to Fail?

Ethical issues in human subjects research

Diastolic Heart Failure

Imaging of Coronary Artery Disease: II

The relationship between adolescent/young adult BMI and subsequent non-problem and problem alcohol use

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef

Top 10 Facts in Contrast Echocardiography. Pamela R. Burgess, BS, RDCS, RDMS, RVT, FASE

INNOVATION THAT REALLY MATTERS. Prof. Lina Badimon. Institut Català de Ciències Cardiovasculars (ICCC), Barcelona

Getting the Most Out of Stress Echo

Microvascular Disease: How to Diagnose and What s its Treatment

Cells and reagents. Synaptopodin knockdown (1) and dynamin knockdown (2)

Transcription:

Washington University School of Medicine Digital Commons@Becker Conference Abstracts and Posters Division of Emergency Medicine/Emergency Care Research Section 2011 Cardioprotection by endogenous fibroblast growth factor 2 in cardiac ischemia-reperfusion injury in vivo Stacey House Washington University School of Medicine in St. Louis Carla Weinheimer Washington University School of Medicine in St. Louis Attila Kovacs Washington University School of Medicine in St. Louis David Ornitz Washington University School of Medicine in St. Louis Follow this and additional works at: http://digitalcommons.wustl.edu/em_conf Recommended Citation House, Stacey; Weinheimer, Carla; Kovacs, Attila; Ornitz, David, Cardioprotection by endogenous fibroblast growth factor 2 in cardiac ischemia-reperfusion injury in vivo (2011). Conference Abstracts and Posters. Paper 7. http://digitalcommons.wustl.edu/ em_conf/7 This Presentation Paper is brought to you for free and open access by the Division of Emergency Medicine/Emergency Care Research Section at Digital Commons@Becker. It has been accepted for inclusion in Conference Abstracts and Posters by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.

Cardioprotection by Endogenous Fibroblast Growth Factor 2 in Cardiac Ischemia- Reperfusion Injury In Vivo Stacey House MD PhD, Carla Weinheimer MS, Attila Kovacs MD, and David Ornitz MD PhD Washington University in St. Louis School of Medicine Society for Academic Emergency Medicine Great Plains Regional Research Forum St. Louis, MO. September 2011 Stacey House, 2011

Fibroblast Growth Factor 2 22 different FGF family members (10 in heart) FGF2 or basic FGF first member of the FGF family identified, expressed fairly ubiquitously FGF2 expressed in all developmental stages of heart; found in cardiomyocytes, fibroblasts, endothelium FGF2 known functions: Hematopoiesis Angiogenesis Wound Healing Mesoderm Induction Cell Survival/Death Cardiac Hypertrophy

FGF2 Isoforms FGF2 mrna (1) (484) (951) 5 AUG (486) CUG (86) CUG (319) CUG (346) CUG (361) Stop(951) 3 HMW LMW 34 kda 24 kda 22.5 kda 22 kda 18 kda nuclear cytoplasmic Nuclear localization signal

FGF2 and Cardioprotection Isolated work-performing global low-flow IR injury- Fgf2 KO have worsened post-ischemic function Cardiac-specific human FGF2 Tg have -improved post-ischemic cardiac function -reduced infarct size FGF2-induced cardioprotection mediated through PKC, MAPK, and NOS signaling

What is the in vivo cardioprotective efficacy of FGF2?

FGF2 Knockout Targeted ablation of all isoforms of FGF2 Viable and fertile No difference from wildtype with respect to cardiac morphometry, function, or vessel density

Closed Chest Ischemia-Reperfusion Instrumentation 90 min Ischemia 7 Days 7 Days Reperfusion Echo Day 1 Echo Day 7 From Dewald et al. 2004

Echo Determination of Ejection Fraction

Endogenous FGF2 in Cardiac Function Post IR Injury 80 Wildtype 70 FGF2 KO Ejection Fraction % 60 50 40 30 20 * * 10 0 1 day 7 day n=6 *p<0.05 vs. wildtype

Echo Analysis of LV Wall Motion Abnormalities

Echo Analysis of LV Wall Motion Abnormalities 50 Wildtype 45 40 * * FGF2 KO % Infarct Size 35 30 25 20 15 10 5 0 1 day 7 day n=6 *p<0.05 vs. wildtype

Trichrome Staining of Fibrosis Wildtype Fgf2 KO

Picosirius Red Stain of Collagen Fibrils

Endogenous FGF2 Effect on Cardiac Hypertrophy Heart Wt vs. Body Wt Ratio 0.01 0.009 0.008 0.007 0.006 0.005 0.004 0.003 0.002 Wildtype FGF2 KO 0.001 0 Heart Wt vs. Body Weight Ratio n=7

Myocyte Area Staining Wildtype Fgf2 KO

Myocyte Cross Sectional Area Post IR Injury Myocyte Cross Sectional Area (um 2 ) 400 350 300 250 200 150 100 50 0 Wildtype Fgf2 KO n=6

Smooth Muscle Actin Staining Wildtype Fgf2 KO

Vessel Density After IR injury SMA (# vessels/10x field) 18 16 14 12 10 8 6 4 2 * Wildtype Fgf2 KO Diameter (µm) 9 8 7 6 5 4 3 2 1 * Wildtype Fgf2 KO 0 0 Vessel Area / 10X field (µm2) 600 500 400 300 200 100 Wildtype Fgf2 KO 0 n=6 *p<0.05 vs. wildtype

Future Directions Analysis of capillary density and vascular remodeling at early time points post IR injury Analysis of inflammatory response post IR injury

Acknowledgements Dave Ornitz Carla Weinheimer Attila Kovacs Sarah Davis Funding Sources American Heart Association Emergency Medicine Foundation Missouri ACEP